BSc, PhD (KC, London)
Chair in Pharmaceutical Industrial Chemistry
- About
-
- Email Address
- j.storey@abdn.ac.uk
- Telephone Number
- +44 (0)1224 272926
- Office Address
- Meston Room G106
- School/Department
- School of Natural and Computing Sciences
External Memberships
Head Chemist for TauRx Therapeutics
- Research
-
Research Overview
Free Radical Chemistry, Organic Methodology, Medicinal Chemistry
Our ability as organic chemists to develop new drugs to combat various diseases depends critically on understanding the behaviour of molecules and using this knowledge to prepare molecules efficiently. It is probably true to say that organic chemistry has reached a point where most molecules can be synthesised given sufficient resources. However, we are far from the position where this can be routinely accomplished in an efficient, atom economical, stereocontrolled and environmentally friendly manner. The major focus of my research effort is, therefore, the development of new synthetic methods and strategies in an attempt to meet some of these shortfalls.
An area that we are particularly interested in is the use of free radical reactions. Radical reactions offer the synthetic organic chemist a number of advantages, which include mild reaction conditions, high levels of regio control and significant functional group tolerance without the need to use protecting groups. We are interested in developing new methods of conducting radical reactions, the use of radical reactions in new bond forming processes and the use of radicals for the synthesis of biologically active compounds of medicinal significance.
Other research areas within the group include mechanistic studies in a variety of reactions, sugar chemistry with a view to the synthesis of biologically active fused carbosugars and tandem bond forming reaction protocols using organochromium compounds. We are also involved in a number of collaborative projects with the medical faculty.
Current Research
Selected Current Projects
- Synthesis of biologically active fused pyridine, pyrimidine and pteridine heterocycles via radical translocation followed by cyclisation.
- A protecting group strategy for the synthesis of C-glycosides, disaccharides and fused carbosugars.
- Iodine atom transfer cyclisation as a route to a range of heterocyclic systems of biological significance.
- New methods of conducting and mediating radical reactions with an emphasis on the development of environmentally friendly systems.
- The use of organic molecules as asymmetric catalysts.
Â
- Teaching
-
Teaching Responsibilities
Professor Storey teaches in the following courses:Â
- CM1010
- CM1011
- CM4017/CM3024 Honours/Advanced Chemistry
- CM5003 MChem Chemistry Applications
Â
- Publications
-
Page 11 of 16 Results 101 to 110 of 153
Making thiosulfate-disubstituted-amino-optionally substituted-phenyl-imino-optionally substituted-cyclohexadienylidene-N,N-disubstituted-ammoniums comprises carrying out nitrosyl reduction, thiosulfonic acid formation and oxidative coupling
Patents: PatentsTau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease
Journal of Alzheimer's Disease, vol. 44, no. 2, pp. 705-720Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3233/JAD-142874
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4205/1/fulltext.pdf
A Twist-Bend Nematic Phase Driven by Hydrogen Bonding
Angewandte Chemie International Edition, vol. 54, no. 2, pp. 643-646Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1002/anie.201409738
Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease
Journal of Pharmacology and Experimental Therapeutics, vol. 352, no. 1, pp. 110-118Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1124/jpet.114.219352
New insights into the liquid crystal behaviour of hydrogen-bonded mixtures provided by temperature-dependent FTIR spectroscopy
Liquid Crystals, vol. 42, no. 5-6, pp. 928-939Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1080/02678292.2015.1037122
Tau-aggregation inhibitor therapy for Alzheimer's disease
Biochemical Pharmacology, vol. 88, no. 4, pp. 529-539Contributions to Journals: ArticlesTauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX
13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, pp. S26Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1016/j.neurobiolaging.2014.01.128
New phenothiazine diaminium compounds are tau protein aggregation inhibitors, useful to treat e.g. Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia and frontotemporal lobar degeneration syndromes
Patents: PatentsThe crystalline state of methylene blue: a zoo of hydrates
Physical Chemistry Chemical Physics, vol. 22, no. 14, pp. 8074-8082Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1039/C2CP40128B
EPR studies of electron and hole trapping in titania photocatalysts
Catalysis Today, vol. 182, no. 1, pp. 39-45Contributions to Journals: Articles